On March 18, 2014, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and Square 54 Office Owner LLC (the “Landlord”) entered into a lease amendment for Vanda’s headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, DC (the “Lease Amendment”). Under the Lease Amendment, Vanda shall have the right to occupy an additional 8,860 square feet in the building. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares after opening at $16.63 moved to $18.14 on last trade day and at the end of the day closed at $16.62. Company price to sales ratio in past twelve months was calculated as 16.32 and price to cash ratio as 4.24. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) showed a negative weekly performance of -10.11%.
22nd Century Group Inc. (NYSEMKT:XXII) shares are in a big breakout yesterday, trading above average volume. The transition from OTC listing to NYSE is having its impact on the stock and all that is positive. Once viewed as a falling knife which everyone tried to avoid, the stock has completed its fall – at least it doesn’t look able to fall any more.22nd Century Group Inc. (NYSEMKT:XXII) shares fell -1.86% in last trading session and ended the day on $3.16. XXII return on equity ratio is recorded as 427.90% and its return on assets is -468.20%. 22nd Century Group Inc. (NYSEMKT:XXII) yearly performance is 247.25%.
On March 17, 2014, Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE) entered into an Addendum No. 4 to the Sponsored Research Agreement, dated September 1, 2009 by and among the Company, Trauma Research LLC and Luoxis Diagnostics, Inc., a subsidiary of the Company. Ampio Pharmaceuticals Inc. (NYSEMKT:AMPE) shares moved down -8.06% in last trading session and was closed at $5.70, while trading in range of $5.66 – $6.30. Ampio Pharmaceuticals Inc. (NYSEMKT:AMPE) year to date (YTD) performance is -20.06%.
Inovio Pharmaceuticals (NYSE:INO) saw a significant growth in short interest in January. As of March 14th, there was short interest totaling 24,207,003 shares, a growth of 6.3% from the February 28th total of 22,762,993 shares, Analyst Ratings Network reports. Approximately 11.4% of the shares of the stock are short sold. Based on an average daily volume of 6,764,778 shares, the short-interest ratio is currently 3.6 days. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) weekly performance is -15.45%. On last trading day company shares ended up $3.23. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) distance from 50-day simple moving average (SMA50) is 6.96%. Analysts mean target price for the company is $4.60.